Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced a key milestone on March 7, 2023, as the USPTO granted a notice of allowance for the patent covering its investigational therapy Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). This patent is expected to be Orange Book-listable with an expiration in 2039, enhancing Trevi's intellectual property portfolio. Currently, there are no approved treatments for chronic cough in IPF, affecting approximately 140,000 patients in the U.S. Haduvio is a mixed opioid receptor therapy that aims to address this significant health issue.
Trevi Therapeutics (NASDAQ: TRVI) announced its participation in several upcoming conferences in March 2023. The events include the Frazier/Fenwick Winter Investor Event from March 7-10, the Oppenheimer 33rd Annual Healthcare Conference on March 13-15 with a corporate presentation on March 13 at 4:00 p.m. ET, and BIO-Europe Spring on March 20-22 (in-person) and March 28-30 (virtual). Trevi is focused on Haduvio™ (oral nalbuphine ER) for chronic cough treatment in adults with idiopathic pulmonary fibrosis and prurigo nodularis, reporting positive results from its Phase 2 CANAL trial.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Emerging Growth Conference on February 22, 2023, at 10:50 a.m. ET. The presentation will focus on its investigational therapy Haduvio™ (oral nalbuphine ER) targeting chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis. Senior leadership, including Jennifer Good, David Clark, and Farrell Simon, will engage in a Q&A session following the presentation. Interested parties can register for the event and access the live webcast on Trevi’s website, with an archived replay available post-event.
Trevi Therapeutics plans to present its investigational therapy Haduvio™ at two major investor conferences in February 2023. The BIO CEO & Investor Conference will take place from February 6-9, with Trevi’s presentation scheduled for February 7 at 10:45 a.m. ET. The SVB Securities Global Biopharma Conference follows from February 13-16, where a presentation is set for February 14 at 11:20 a.m. ET. Trevi Therapeutics, trading under the symbol TRVI, is developing Haduvio for chronic cough and prurigo nodularis, having reported promising Phase 2 trial results for chronic cough in patients with idiopathic pulmonary fibrosis.
Trevi Therapeutics (Nasdaq: TRVI) announced significant business updates on Jan. 5, 2023, highlighting the progression of its investigational therapy, Haduvio™. Aiming to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, Trevi is preparing for several clinical studies in 2023, including a Phase 2 dose-ranging study and a Phase 1b respiratory physiology study. The company is also conducting a human abuse liability study and will request an End-of-Phase 2 meeting with the FDA. Trevi will participate in key conferences starting January 9, 2023.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Biotech Showcase 2023 on January 10, 2023, at 3:00 p.m. PT. This event coincides with the 12th Annual LifeSci Partners Corporate Access Event, held from January 9-11, 2023, in San Francisco, CA. Trevi is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough and prurigo nodularis. Positive results from the Phase 2 CANAL trial for chronic cough related to idiopathic pulmonary fibrosis have prompted Trevi to prioritize further clinical development in this area.
Trevi Therapeutics has appointed David Clark, MD, MRCP, as the new Chief Medical Officer to advance the development of Haduvio™, an oral investigational therapy for chronic cough related to idiopathic pulmonary fibrosis. Dr. Clark brings over 25 years of experience in clinical development and has previously led clinical teams at several biopharmaceutical companies. He will play a critical role in executing Trevi's clinical strategies, supported by the insights from prior CMO Thomas Sciascia, who transitions to Chief Science Officer.
Trevi Therapeutics (TRVI) reported its Q3 2022 financial results, highlighting a net loss of $8.3 million, up from $7.3 million year-over-year, largely due to increased R&D expenses of $5.8 million. The clinical-stage biopharmaceutical firm announced significant progress in its Phase 2 CANAL trial for Haduvio, showing a 75.1% reduction in cough frequency in IPF patients, backed by statistically significant data. Trevi ended the quarter with approximately $126 million in cash and equivalents, poised to fund further development.
Trevi Therapeutics (Nasdaq: TRVI) announced participation in the Stifel 2022 Healthcare Conference on November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT. CEO Jennifer Good and CFO Lisa Delfini will be present for a fireside chat discussing their investigational therapy Haduvio™ for chronic cough. A live audio webcast will be available on their website, with an archive accessible post-event. Trevi focuses on developing Haduvio, which has shown positive results in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide a corporate update. The focus will be on its investigational therapy, Haduvio, for chronic cough conditions. The company has completed a Phase 2 trial for Haduvio's efficacy in treating chronic cough linked to idiopathic pulmonary fibrosis (IPF) and aims to target further development in chronic cough conditions including IPF and refractory chronic cough.